Article

Pregabalin Reduces the Release of Synaptic Vesicles from Cultured Hippocampal Neurons

Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305, USA.
Molecular Pharmacology (Impact Factor: 4.13). 09/2006; 70(2):467-76. DOI: 10.1124/mol.106.023309
Source: PubMed

ABSTRACT

Pregabalin [S-[+]-3-isobutylGABA or (S)-3-(aminomethyl)-5-methylhexanoic acid, Lyrica] is an anticonvulsant and analgesic medication that is both structurally and pharmacologically related to gabapentin (Neurontin; Pfizer Inc., New York, NY). Previous studies have shown that pregabalin reduces the release of neurotransmitters in several in vitro preparations, although the molecular details of these effects are less clear. The present study was performed using living cultured rat hippocampal neurons with the synaptic vesicle fluorescent dye probe FM4-64 to determine details of the action of pregabalin to reduce neurotransmitter release. Our results indicate that pregabalin treatment, at concentrations that are therapeutically relevant, slightly but significantly reduces the emptying of neurotransmitter vesicles from presynaptic sites in living neurons. Dye release is reduced in both glutamic acid decarboxylase (GAD)-immunoreactive and GAD-negative (presumed glutamatergic) synaptic terminals. Furthermore, both calcium-dependent release and hyperosmotic (calcium-independent) dye release are reduced by pregabalin. The effects of pregabalin on dye release are masked in the presence of l-isoleucine, consistent with the fact that both of these compounds have a high binding affinity to the calcium channel alpha(2)-delta protein. The effect of pregabalin is not apparent in the presence of an N-methyl-d-aspartate (NMDA) antagonist [D(-)-2-amino-5-phosphonopentanoic acid], suggesting that pregabalin action depends on NMDA receptor activation. Finally, the action of pregabalin on dye release is most apparent before and early during a train of electrical stimuli when vesicle release preferentially involves the readily releasable pool.

Download full-text

Full-text

Available from: Charles P Taylor, Jan 27, 2016
  • Source
    • "They are both structural analogues of the inhibitory neurotransmitter ϒ-aminobutyric acid. They are responsible for inhibition of calcium influx and reduced neurotransmitter release of glutamine, norepinephrine, and substance P at the central nervous system, with suppression of neuronal excitability after nerve or tissue injury[84]. They have proven to be effective in reducing post-operative pain and opioid consumption[85], but studies concerning shoulder pain are still very few and inconclusive[86]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Minimal invasive surgery has well-known advantages. The majority of procedures performed on the kidney are now-a-days laparoscopic, with several advantages over laparotomy: decreased perioperative morbidity and mortality, smaller incisions, faster recovery, shorter hospital stays and earlier return to active life. Postoperative pain is the most common complaint and an important issue following laparoscopic surgery. There are different theories proposed to explain omalgia: distension of the peritoneal blood vessels and nerves during pneumoperitoneum, the associated in ammatory reaction (release of proin ammatory cytokines), rate of CO2 infusion; distension of the triangular and round ligament; time of exposure to the gas; gas retention inducing irritation of the phrenic nerve; nerve injury during patient positioning (shoulder abduction) and diaphragm injury. Debate still exists on how to minimize it. We review the different etiologic mechanisms and proven and potential preventive measures and treatments on how to avoid post- operatory pain: proper patient positioning, pulmonary recruitment maneuvers, intraperitoneal normal saline infusion, using gabapentin, pregabalin, irrigation with bupivacaine, using NSAIDs, opioids and hydrocortisone.
    Full-text · Article · Oct 2015
  • Source
    • "The current findings are consistent with others that indicate that PGB is clinically effective in managing neuropathic pain[59 – 61]. It binds to α 2 -δ 1 subunit of the voltage-gated calcium-gated channels, decreasing the release of glutamate, norepinephrine and substance P and preventing the binding of the neurotransmitter to their receptor , thus reducing the neuronal hyperexcitability[62,63]. These effects and other cellular enzymatic cascade reactions induced by PGB may result in decreased sensitivity to pain. "
    [Show abstract] [Hide abstract]
    ABSTRACT: : The hydro-ethanolic extract of : Neuropathic pain was induced in Sprague-Dawley rats by injecting 100 μg/kg of vincristine sulphate on alternative days for 6 days (days 0, 2, 4, 8, 10 and 12). Vincristine-induced cold allodynia, mechanical hyperalgesia and thermal hyperalgesia were measured pre-vincristine administration and on days 15, 17 and 19 post-vincristine administration. The rats were then treated with SNE and pregabalin produced analgesic properties observed as increased paw withdrawal latencies to mechanical, tactile, cold water stimuli and thermal hyperalgesic tests during the 5 days of treatment. : The findings suggest that hydro-ethanolic extract of
    Full-text · Article · Jan 2015 · Journal of basic and clinical physiology and pharmacology
  • Source
    • "These compounds are useful in the treatment of a number of disorders, including epilepsy, but their modes of action are nonselective , and therefore, conclusions regarding the effects on GABA, particularly synaptic, are difficult to draw. The activity of these anticonvulsants include, but are not limited to, sodium and calcium channel modulation, mitochondrial neuroprotection, manipulation of the equilibrium with other neurotransmitters , and enzymatic induction or inhibition (Hendrich et al., 2008; Kudin et al., 2004; Micheva et al., 2006; Petroff et al., 1999a; Rogawski, 2006). More selective compounds, which modulate GABA directly, provide more pertinent tests of MRS sensitivity . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Though GABA is the major inhibitory neurotransmitter in the brain, involved in a wide variety of brain functions and many neuropsychiatric disorders, its intracellular and metabolic presence provides uncertainty in the interpretation of the GABA signal measured by 1H-MRS. Previous studies demonstrating the sensitivity of this technique to pharmacological manipulations of GABA have used non-specific challenges that make it difficult to infer the exact source of the changes. In this study, the synaptic GABA reuptake inhibitor tiagabine, which selectively blocks GAT1, was used to test the sensitivity of J-difference edited 1H-MRS to changes in extracellular GABA concentrations.MEGA-PRESS was used to obtain GABA-edited spectra in 10 male individuals, before and after a 15 mg oral dose of tiagabine. In the three voxels measured, no significant changes were found in GABA+ concentration after the challenge compared to baseline. This dose of tiagabine is known to modulate synaptic GABA and neurotransmission through studies using other imaging modalities, and significant increases in self-reported sleepiness scales were observed. Therefore it is concluded that recompartmentalisation of GABA through transport block does not have a significant impact on total GABA concentration. Furthermore, it is likely that the majority of the MRS-derived GABA signal is intracellular. It should be considered, in individual interpretation of GABA MRS studies, whether it is appropriate to attribute observed effects to changes in neurotransmission. Synapse, 2014. © 2014 Wiley Periodicals, Inc.
    Full-text · Article · Aug 2014 · Synapse
Show more